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Patient-derived metabolomics offers valuable insights into the
metabolic phenotype underlying diseases with a strong meta-
bolic component. Thus, these data sets will be pivotal to the
implementation of personalized medicine strategies in health
and disease. However, to take full advantage of such data sets,
they must be integrated with other omics within a coherent
pathophysiological framework to enable improved diagnostics,
to identify therapeutic interventions, and to accurately stratify
patients. Herein, we provide an overview of the state-of-the-art
for different data analysis and modeling approaches applicable
to metabolomics data and of their potential for systems
medicine.
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Systems biology treats biological systems as ensembles
of networks at multiple levels, starting from the mo-
lecular level and from there gradually addressing more
complex systems such as cells, tissues, organs, whole
organisms, and finally analyzing population dynamics.
Systems biology aims to describe and predict the
behavior of groups of interacting components. To do so,
it uses mathematical and computational tools to analyze
measurements collected by systematic high-throughput
technologies such as (post)genomics, metabolomics, or
proteomics among others. The goal of systems ap-
proaches is to boost our understanding of biology by
overcoming the limitations of reductive science, which
addresses individual genes, proteins, metabolites,
pathways, or cells, and thus does not account for the
properties emerging from their interactions [1,2].
Current medical science is mostly conducted using the
reductionist approach [3,4]. This limits our ability to
grasp how multiple variables interact with one another
to create emergent effects [3] and hampers our under-
standing of diseases, as well as our capability of deliv-
ering better treatments. Systems medicine can be
regarded as the application of systems biology to human
physiology in a clinical context [5,6]. It addresses the
aforementioned issues by applying iterative and recip-
rocal feedback between clinical research and practice
through computational, statistical, and mathematical
multiscale analysis. This includes modeling of disease
progression and remission, treatment responses, and
adverse events both at the epidemiological and patient
level. This new paradigm of systems science and med-
icine strongly complements the traditional reductionist
approach (Figure 1).
The functioning of the human body is regulated by the
interaction and interdependencies of biological mole-
cules at multiple levels (proteineprotein, proteine
RNA, and proteineDNA networks and metabolic net-
works) [8]. Therefore, it can only be efficiently analyzed
by examining various omics concurrently. Systems





Overview of the core differences between reductionism and systems science, when analyzing the properties of a system; figure initially published in










































































































COISB239_proof ■ 15 April 2019 ■ 2/9this goal. The complementary perspectives offered by
different data sets allow the genotype of an individual to
be linked to its observed phenotype as a function of
lifestyle and environmental conditions. Eventually, this
could lead to defining how any healthy state can tran-
sition into a pathological one and vice versa and pave the




















The integration of multiple omics data (sometimes also
called trans-omics) will further enhance the contribu-
tion of omics science to our understanding of biomedi-
cine [9]. The example in Figure 2 shows the
connections among genomics, transcriptomics, prote-
omics, and metabolomics, thus providing an overview of
the system from its potential (encoded in DNA) to the
actual outcome (monitored by metabolomics).
It is commonly accepted that the relationships between
genes, gene products, and metabolites participate in
complex, interconnected networks (Figure 2). Various
biological molecules can be represented as nodes in a
network and the interactions connecting them as edges.
For example, in metabolomics, metabolites would be the
nodes, and the edges would represent the enzymatic
reactions interconnecting them. Graph theory can beCurrent Opinion in Systems Biology xxxx, xxx:xxxapplied to analyze the complexity of the interactions
within a biological network and link a priori knowledge
from the literature and databases [11]. The application
of network analysis allows the identification of nodes
with a high degree of connectivity (‘hubs’) and groups of
highly interconnected nodes (‘modules’), identifying
molecules functionally related to a disease state [12e
14].
It is possible to outline a general strategy to integrate
various omics data sets based on network representa-
tions. First, the network scaffold is defined by defining
how the individual components are interconnected. The
structure of the network can be identified based on the
data or prior knowledge (i.e., database information).
Subsequently, the network itself can be separated into
modules. Finally, all the information can be combined
with computational models of the whole system to
simulate and predict how the network determines the
observed phenotype. In practice, if two omics elements
share a common driver, or if one perturbs the other, they
will exhibit correlation or association. Various specialized
statistical approaches can be applied to measure these
correlations. For example, a linear model taking into
account age, gender, body mass index, and white blood





Multi-omics integration across different omics layers. Red arrows highlight
the top-down flow of interactions across layers: genes are transcribed,
transcripts determine enzyme concentrations, and finally enzymes act on
metabolites. Purple arrows highlight the bottom-up interactions, whereby
metabolite levels modulate enzyme activities, the DNA/RNA-binding af-
finities of regulators or DNA methylation. Note that metabolites can also
interact directly with transcripts. Black arrows are intra-omics networks,
which can be derived based on individual omics data sets (for a review of
methods in metabolomics, see Rosato et al., 2018 [10]). Intra-omics
networks may describe direct physical interactions (e.g., protein–protein
interactions) and correlations between their abundances (e.g., transcript
levels or metabolite concentrations). Environmental stimuli (blue arrows)
can affect all omics layers. For example, they can trigger DNA mutations
and transcriptional events and modify protein activity. In addition, the
environment is also a source of metabolites and xenobiotic molecules.
Overall, the different omics levels, which are a function of the environment
and the omics interactions, determine the phenotype.





























































































































COISB239_proof ■ 15 April 2019 ■ 3/9methylation and metabolite concentrations in human
blood serum [15]. An even broader study analyzed the
genome, transcriptome, proteome, metabolome, and
metabolic fluxes in Escherichia coli to understand how its
metabolic state reacted to perturbations [16]. More
recently, weighted gene correlation network analysis was
used to identify connectivity-based gene modules highly
correlated to pathways identified by metabolomics [17].
Connecting the metabolome layer and other omics
layers
Metabolomics measures the metabolites present within
a cell, tissue, or organism. It is a core experimental omics
within systems biology as it delivers an integrated view
of biochemistry [18,19]. Current experimental ap-
proaches in metabolomics are mostly based on nuclear
magnetic resonance and mass spectroscopy [20,21].
Metabolomic studies can be divided into two major
groups: targeted and untargeted.
Targeted metabolomics quantitatively measures the
abundance of a predefined group of known, well-
characterized metabolites in a sample. Usually, the aim
is to identify novel associations between metabolites in
the context of specific physiological states [22,23]. Onwww.sciencedirect.comthe other hand, untargeted metabolomics typically fo-
cuses on capturing all the chemical compounds present
in a sample, including metabolites of unknown chemical
structure, thus generating notably large data sets. By
comparing the metabolome of the control and test
groups and focusing on the differences between their
metabolic profiles, the number of significant detected
signals becomes more manageable. Finally, the com-
pounds or metabolites identified are annotated using in
silico libraries when possible or by applying analytical
chemistry methods to explore the newly observed
structure [24].
One of the technical challenges in connecting the
metabolome with other omics layers is matching the
identities of the same objects in different layers (ID
conversion). Various databases support this task: the
Kyoto Encyclopedia of Genes and Genomes (KEGG)
integrates one computationally generated and fifteen
manually curated databases, allowing the users to link
metabolites to reactions, enzymes, pathways, and genes
[25]; BRENDA provides information on enzymes, such
as kinetic parameters for enzymatic reactions, allosteric
effectors, and associationwith diseases [26]; Reactome is
a database that organizes metabolites into biological
pathways and processes, using reactions to define re-
lationships [27]; and MetaCyc is a database of metabolic
pathways and enzymes, whereas BioCyc (BioCyc.org)
collects organism-specific genomes and computationally
predicted metabolic networks [28]. For example, in a
multi-omics study on the flow of the insulin signal based
on time course data from the metabolome, phosphopro-
teome, and transcriptome, a global metabolism map was
generated by mapping quantitatively changed metabo-
lites and their corresponding metabolic enzymes to the
KEGG database [29].
Finally, it is worth mentioning the Investigation/Study/
Assay (ISA-Tab) format, which is a convenient standard
to store the metadata and the results of experiments
across the various omics, is already implemented in
metabolomic platforms such as MetaboLights or
PhenoMeNal [30e32].Metabolic models
The metabolic phenotype is defined by two comple-
mentary omics, the metabolome and the fluxome. The
first offers a static view of metabolism (snapshot-like),
whereas the latter represents the rate at which metab-
olites are interconverted through metabolic pathways
and therefore provides a dynamic view of the metabolic
phenotype [33]. The fluxome emerges from complex
interactions among metabolites, enzymes, and trans-
membrane carriers. Thus, the fluxome cannot be
directly measured and instead needs to be inferred
through the analysis of other omics measurements. One































































































































COISB239_proof ■ 15 April 2019 ■ 4/9fluxome is stable isotope-resolved metabolomics
(SIRM). In SIRM, a biological system is incubated with
a substrate labeled with a stable heavy isotope (e.g.,
13C) that propagates to metabolites in the network
generating characteristic label patterns which are
indicative of the underlying flux distribution [34].
Metabolic models, mathematical representations of
metabolism, are the tools used by systems biology and
systems medicine to integrate multiple layers of data
and predict metabolic fluxes. Nowadays, the vast avail-
ability of genomic data and the functional annotations
allows the reconstruction of genome-scale metabolic
models (GSMMs). GSMMs are built starting from
genome annotations, which are used to identify enzyme-
coding genes. These can then be mapped to reactions
using biochemical databases, such as KEGG, BRENDA,
or MetaCyc. The resulting network is then curated to
account for misannotations and missing reactions.
Finally, the built reconstruction is validated by simu-
lating the known metabolic functions of the target or-
ganism [35]. In 2007, the first human GSMMs were
reconstructed [36,37]. They formed the basis for much
more in-depth human genome-scale reconstruction
models including Human Metabolic Reaction, Recon 2,
and Recon3D [38e40].
Metabolic simulations based on these genome-scale
networks, or a subset of them, are usually performed
with either kinetic- or constraint-based modeling
(CBM) techniques. Kinetic models integrate kinetic
properties of enzymes (e.g., their affinity for substrates,
the number of catalytic cycles that they can undergo per
unit of time, and their regulation by activators or in-
hibitors) and allow to simulate the dynamic behavior of
fluxes and metabolites. However, they are limited by the
complexity to build and parametrize kinetic models for
large networks. In contrast, CBM uses network stoi-
chiometry and the assumption of the metabolic pseudo-
steady state (i.e., intracellular metabolite concentra-
tions are constant in time) to simulate steady-state flux
distributions. Although CBM is easily applied to large
networks such as GSMMs, it has a more limited capacity
when it comes to studying the dynamic behavior of
metabolic networks than kinetic models.
Building large-scale kinetic models
Kinetic models are systems of ordinary differential
equations (ODEs) where metabolic fluxes are
computed as a function of metabolite concentrations
through a set of defined kinetic equations. Each
metabolite has an ODE equation representing its vari-
ation in time, and each reaction has a kinetic equation
describing the dependency of reaction fluxes to
metabolite and enzyme concentrations. Metabolomic
data, taken at multiple time points, are the primary
input to validate kinetic models and iteratively fitCurrent Opinion in Systems Biology xxxx, xxx:xxxunknown parameters of the kinetic equations (Figure 3)
[41].
There are two approaches to building large-scale kinetic
models: the bottom-up or forward reconstruction and
the top-down or inverse reconstruction. In the former
method, the various subparts of the model are built
individually and then put together to form the final
model, whereas in the latter, the entire model is
reconstructed, and all the parameters are fitted at the
same time. The major issues in large-scale kinetic model
reconstruction are the many unknown parameters in the
model and the lack of knowledge of regulatory infor-
mation. Indeed, the greatest challenge to build large
kinetic models is the parameter inference or fitting step.
Over the last few years, approaches such as structural
kinetic modeling and mass action stoichiometric simu-
lation (MASS) modeling have been developed to tackle
this step.
Structural kinetic modeling aims to quantitatively
describe the dynamic performance of a system, rather
than specifically define kinetic parameters, and con-
structs local linear approximations for each parameter
according to experimental data and feasible biochemical
states. Then, the reconstructed local linear models are
used for the interrogation of a solution parameter space
[43,44]. On the other hand, MASS models try to
combine constraint-based stoichiometric re-
constructions with matrix-based kinetic modeling. More
specifically, MASS uses large-scale stoichiometric
network reconstructions as scaffolds, onto which fluxo-
mic and metabolomic data measured in vivo are inte-
grated, and then, kinetic parameters, explicit for the
modeled steady state of the system, are estimated. If
simulations of growth conditions are performed, kinetic
constants for the evolution of the system can be calcu-
lated, thus describing its dynamic behavior [45].
Constraint-based modeling
CBM assumes a metabolic pseudo-steady state to build
mass balance constraints around metabolites and iden-
tify valid steady-state flux distributions. In this manner,
the stoichiometry of the network can be represented as
a system of linear equations, and steady-state flux dis-
tributions can be simulated without the need for
defining the kinetic equations for each enzyme
[36,37,46]. As the resulting system is usually under-
determined, additional constraints and optimizations
need to be applied to reduce the solution space toward a
unique solution (Figure 4) [38,39].
For instance, GSMMs generally need to be constrained
by integrating transcriptomics or proteomics data. This
need arises because GSMMs define the entire meta-
bolic potential for a given organism, whereas at any given





Kinetic model of upper glycolysis (Puigjaner et al., 1997 [42]). The Q4network has four metabolites (Glc: glucose, G6P: glucose 6-phosphate, F6P: fructose
6-phosphate) connected by three reactions (HK: hexokinase, GPI: glucose 6-phosphate isomerase, PFK: phosphofructokinase). HK has a Michaelis–
Menten kinetic law with an uncompetitive inhibition by G6P; GPI, a reversible Michaelis–Menten kinetic law; and PFK, a Hill cooperative kinetic law. Each
kinetic law is parametrized from measurements of mice muscle extracts (Vmax: maximal reaction rate, Km/Kms/Kmp/Shalve: concentration at which half of
the Vmax is achieved, Ki: Concentration at which half of the inhibition is achieved, h: Hill cooperativity coefficient). From network stoichiometry, the
parametrized kinetic laws are combined to build a system of ODEs, with each equation describing the dependent dynamic of a metabolite concentration.
Starting with initial metabolomic values, solving the system of ODEs simulates time courses for metabolite concentrations and reaction fluxes, which can
be compared with additional metabolomics data for validation. ODE, ordinary differential equation.
Metabolomics in systems medicine Karakitsou et al. 5
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Figure 4
Constraint-based modeling. First, the stoichiometry of the metabolic network is written as a stoichiometric matrix (s), where the sm,r element of the matrix
is the stoichiometric coefficient of the metabolite m in the reaction r. From an infinite space of possible flux (v) solutions, a feasible solution space which
contains possible steady-state solutions is obtained by applying the steady-state constraint (s.v = 0) and defining the directionality of reactions. A
condition-specific solution space can be obtained by integrating condition-specific omics such as transcriptomics, proteomics, or metabolomics. Finally,
an optimization can be performed in the solution space to select the best solution(s). For instance, biomass production can be maximized so that the






























































































































COISB239_proof ■ 15 April 2019 ■ 6/9expressed and only a subset of reactions will be active.
There are several approaches to integrate such data, but
they are generally based on maximizing the consistency
between the transcript and protein abundances of en-
zymes and the flux through reactions catalyzed by them.
Integrating transcriptomics and proteomics allows to
obtain maps of active/inactive reactions, as well as to
characterize the changes in flux distributions betweenCurrent Opinion in Systems Biology xxxx, xxx:xxxtwo or more different conditions or time points [47e
52].
The range of feasible flux values can be further
constrained by metabolomics data. Metabolomics from
the extracellular media can be used to constrain extra-
cellular fluxes (i.e., rates of uptake of secretion for

































































































































COISB239_proof ■ 15 April 2019 ■ 7/9metabolomics, if a metabolite is detected, the model
can be constrained to have at least one reaction active,
where this metabolite is produced [50]. Furthermore,
quantitative metabolomics of intracellular metabolites
allows setting the rate at which intracellular metabolites
must be synthesized to maintain a steady state in
proliferating or growing systems [53]. Finally, SIRM-
based metabolic flux analysis can be applied to iden-
tify the range of flux values underlying a given set of
SIRM measurements. The resulting flux ranges can be
added to the GSMM as flux bounds [34].
Even after integrating transcriptomics or proteomics and
metabolomics, GSMMs are generally still undeter-
mined. Flux balance analysis aims to identify a unique
optimal solution by maximizing or minimizing one or
more fluxes in the metabolic network [54]. The choice
of objective depends on the system under study, for
instance, to study rapidly proliferating systems, such as
cancer cells, the synthesis of biomass is used as the
objective, but other objectives can be set depending on
the system of study [54e59].
Applications in systems medicine
The integration of multiple omics data in a systems
medicine manner is an emerging field. Nevertheless, it
has already provided new insights into the interplay
among different regulatory layers.
For example, by studying the associations between
SNPs and metabolomics measurements, it has been
demonstrated that the variability of metabolite con-
centrations in the blood between individuals is
explained to a large extent by common genetic variants
[60]. In another study, associations using epigenome-
wide association data in combination with cytosinee
guanine dinucleotide methylation data and other
multi-omics data suggested a causal effect of metabolite
levels on methylation of obesity-associated cytosinee
guanine dinucleotide sites [61].
Furthermore, even if the reconstruction of large-scale
kinetic models still poses a big challenge, several ex-
amples of kinetic models in systems medicine demon-
strate their great potential. For instance, a kinetic model
of human erythrocytes was used to identify metabolic
targets that would selectively kill the parasite Trypano-
soma brucei with minimal collateral damage to human
cells [62]. Berndt et al. [63] reconstructed a kinetic
model of the liver, and they used it to characterize the
metabolic phenotype of hepatocytes and the metabolic
reprogramming that they have undergone during carci-
nogenesis. Bordbar et al. [64] have simulated individual
responses to drug exposure including side effect inci-
dence and demonstrated that enzyme activities and
cellular dynamics, rather than metabolomics, are the
most accurate representation of the genotype.www.sciencedirect.comCBM has also been widely used in systems medicine to
perform multi-omics data integration in the framework
of GSMMs. For example, Mardinoglu et al. [65] inte-
grated proteomics and transcriptomics to build an
adipocyte-specific GSMM and identified several puta-
tive therapeutics against obesity. GSMMs have also
been widely applied to identify genes or sets of genes
that are essential for a disease-related process [59,66e
68]. For instance, Folger et al. [69] created a GSMM
of cancer metabolism that predicted 52 cytostatic drug
targets, 40% of which were targeted by known anti-
cancer drugs. Similarly, Agren et al. [70] built 27
patient-specific GSMMs of hepatocellular carcinoma
and identified 101 potential drug targets, many of which
had a strong correlation with disease progression.
GSMMs have also shown great potential in biomarker
discovery, for example, in liver diseases and type 2 dia-
betes [71,72].124Conclusions and future perspectives
The primary goal of systems medicine is to explain,
predict, and prevent the progression of disease based on
clinical, environmental, and multi-omics data. Given the
inherent network structure of metabolic processes,
network modeling and the analysis of multi-omics data
provide powerful and flexible inference tools to deci-
pher the complex interactions in biological systems.
However, consensus models built from samples from
many individuals, albeit informative, might fail to cap-
ture the heterogeneity that is present in a population
[73]. This limits the elucidation of the molecular drivers
for an individual-specific phenotype (either healthy or
pathological), which result from the differential regu-
lation or dysfunction of individual-specific networks.
Toward that end, methods are being proposed to build
patient-specific networks that capture the subject’s
specificity of clinical manifestation with the goal of
understanding diseases at the individual level and
providing targeted and personalized treatments [74e
77]. In principle, a personalized database could be
generated for each individual, containing his/her omics
information (e.g., genomics, urine and blood metab-
olomics, gut microbiome), together with lifestyle data
across time. This information, if properly analyzed, can
provide the means to build patient-specific networks to
identify the best diagnostic, therapeutic, and prevention
strategies for each individual and enable predictive,
preventive, personalized and participatory medicine
[78,79].
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